Background
==========

Gene testing in primary care is no longer limited by their exorbitant cost. The prices of genetic tests are dropping faster than Moore's law for computing costs \[[@B1]\]. This leads the focus to shift from cost of genetic testing to the clinical value of individual gene tests. The recent development of gene-based tests that predicts the risk of lung cancer in smokers is an important example \[[@B2]\].

Despite the well accepted 10-15% probability of lung cancer in smokers, 50% of smokers do not believe they are at significantly increased risk \[[@B3]\]. However, over 80% of smokers would like to know their personal risk of lung cancer \[[@B4]\]. There is a plausible three way link between biomarkers for chronic obstructive pulmonary disease (COPD), a set of 20 single nucleotide polymorphisms (SNPs) associated with cancer risk and lung cancer \[[@B5]-[@B8]\] (Figure [1](#F1){ref-type="fig"}). Research has shown a strong association between a high lung cancer susceptibility score derived from family history of cancer, the 20 SNPs, COPD history (Auckland formula) and the development of lung cancers whereas healthy smokers matched for age, gender and lifetime smoking habits had a relatively low score (n = 446 lung cancer subjects, 484 healthy current smokers). The odds ratio for lung cancer risk varied from 0.2-3.2 depending on the genetic risk (p \< 0.001) \[[@B9],[@B10]\]. The accuracy of the Auckland formula in estimating lung cancer risk for a score of \>4 was: sensitivity 90%, specificity 45% (Figure [1](#F1){ref-type="fig"} which also includes scores for 52 subjects who developed cancer from a six year prospective study of 1212 smokers and ex-smokers). The score for prediction of non-cancer was conducted with a follow up of just six years. It means that 45% of non-cancer subjects have a low cancer score and 55% have some degree of increased score. The 55% with increased scores have simply not been followed up long enough for lung cancers to develop yet. Notwithstanding this limitation there is now a 20 SNP gene test for prediction of lung cancer in smokers under the trade name *Respiragene*.

![**Research that established the respiragene test.** Distribution of the Respiragene score in a cross-sectional study of 484 control smokers (blue) and 446 with lung cancer (red) (Total = 930) and from the prospective study of 52 lung cancer cases (green). Reference \[[@B8]\].](1471-2466-14-77-1){#F1}

Two case-control studies showed a 5-10% increase in cessation with a single gene test of small effect \[[@B11],[@B12]\]. A small smoking cessation pilot study using spirometry results and explanations using the Fletcher-Peto diagram to explain risk demonstrated that patients find this is an acceptable method and the quit rate at 12 months was 27% \[[@B13]\]. In a randomised control trial patients were given either a full explanation of the results of spirometry testing, including an estimation of lung age or just their forced expiratory volume in the first second (FEV1), without explanation (control group). The group of patients who were given the full explanation had a 7.2% higher quit rate than the control group \[[@B14]\]. Data from a hospital outpatient cohort in Auckland suggest a larger increase in quit rate with *Respiragene* test and the Auckland formula (Table [1](#T1){ref-type="table"}). Subjects, who were current smokers in the pre-contemplative and contemplative stage, were randomised into either the test group or control group and only the test group had the *Respiragene test*. Counselling and follow-up was done by telephone. Using Auckland formula to incorporate the results of the *Respiragene* test, clinical data and family history a score ranging 1-12 with associated risk level (moderate risk, high risk, very high risk) was calculated and explained to test subjects. Neither group were involved in any formal smoking cessation programme. Indeed, of the 13 subjects that had managed to stop smoking, (28% of the gene-tested group), 48% quit without any medical assistance and only 52% had nicotine replacement therapy \[[@B15],[@B16]\]. When compared with previous studies using telephone counselling alone \[[@B17]\] (Figure [2](#F2){ref-type="fig"}), there is a 20-25% improvement in smoking cessation with the *Respiragene* test (Table [1](#T1){ref-type="table"}). The improvement in intention to quit increases from 56% before testing to 67% in smokers with an average smokers risk of lung cancer or 89% in smokers with a high risk of lung cancer \[[@B18]\].

###### 

Respiragene study in Auckland NZ (n = 43)

                                                                                **Cancer susceptibility scale (compared with normal lifetime risk)**   **Cancer susceptibility score**   **Estimated lifetime risk of lung cancer**   **Initial intention to quit**   **Proportion that stopped smoking at 2-4 weeks**   **Proportion still not smoking at 6 months**
  ----------------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------- -------------------------------------------- ------------------------------- -------------------------------------------------- ----------------------------------------------
  Expected result for telephone counselling (Figure [2](#F2){ref-type="fig"})   \-                                                                     \-                                15%                                          41%                             10-20%                                             9-12%
  Telephone counselling + Respiragene test                                      1-2.3 (10-35% risk) 2.3-6.7 (35-65% risk) 6.7-8 (65%-80% risk)         27 had average risk score         15%                                          67%                             8/27 (30%)                                         8 (30%)
  16 had high or very high risk score                                           30-50% (4-10 times average risk)                                       89%                               10/16 (63%)                                  6 (37.5%)                                                                          

Smoking cessation after Respiragene testing and estimation of lung cancer risk with telephone counselling in a small pilot study in Auckland NZ (n = 43) compared with expected quit rate.

![**Efficacy of the variety of smoking cessation strategies.** Percent increase of success for six months over unaided attempts for each type of quitting (chart from West & Shiffman based on Cochrane review data). Totally unaided smoking cessation has a 3-6% success rate. Therefore telephone support (Table [1](#T1){ref-type="table"}) increases success rate by 6% = 9-12% quit rate.](1471-2466-14-77-2){#F2}

A large hospital trial using *Respiragene* for calculating lung cancer susceptibility is currently underway in the USA \[[@B19]\], but there are no planned UK investigations. This study fills that gap and uses the NHS framework for smoking cessation. Other studies have taken place looking at how lung functioning testing in COPD might motivate smokers to quit, suggesting that it is feasible to conduct this sort of study \[[@B13],[@B14],[@B20]\]. This protocol describes a trial to evaluate a gene-based risk test (using genetic and clinical data) as a smoking cessation motivator, in smokers wishing to participate in an NHS primary care smoking cessation clinic (in the action stage of change), alongside the usual counselling and prescribing protocol. It will differ from previous studies using gene testing as a motivator, however, in that the NHS primary care counselling and prescribing protocol will include several other motivators (CO breath testing, saliva cotinine testing and intensive counselling) whereas the Auckland trial, using the same gene test, had none of these. Also, the method of recruitment will differ in that primary care subjects will, of necessity, be different from the Auckland hospital outpatient cohort \[[@B15],[@B16]\].

Research question
-----------------

Can the *Respiragene* test combined with an estimation of lung cancer susceptibility be used to increase the uptake, adherence to and success rate in an established smoking cessation programme in subjects who want to quit in a National Health Service, United Kingdom (NHS UK) setting?

Hypothesis
----------

Genetic testing and estimation of lung cancer susceptibility should increase "smoking cessation outcomes" at six months to \>30% (or 1.5-2 fold greater than usual care) irrespective of the risk scores assigned to subjects \[[@B11]\].

Method/Design
=============

This protocol has been approved by Surrey Research Ethics Committee at the Royal Surrey County Hospital, Guildford, Surrey, UK.

1/Recruitment
-------------

### Focus groups

A number of focus groups of different aged smokers will be held to enable them to contribute to the design of the study

2/ Recruitment
--------------

Subjects will be recruited from a large general practice in Surrey (practice population= \> 30,000). Smokers aged 20-70 years will be identified from the practice records and contacted by post by their GP. Patients who reply stating that they wish to stop smoking will be randomised (stratified randomisation to ensure equivalent age and gender mix) to two clinics (Figure [3](#F3){ref-type="fig"}) only one of which will include the gene-based test. Previous trials of genetic testing in association with smoking cessation achieved 83-100% of participants opting for the test depending on the method of recruitment \[[@B8],[@B21]\]. There will be two mailings with SAEs for recruitment with the aim of recruiting at least 30 subjects per clinic (see Power calculations under heading "statistics"). In the first letter the patient's GP asks the patient to give permission for the researcher to contact him/her to ask about taking part in smoking cessation research (with possible genetic risk testing) and encloses fact sheet 1 and a stamped addressed envelope (SAE) for reply.

![Consort 2010 flow diagram for GeTTS recruitment.](1471-2466-14-77-3){#F3}

Mailing 2. The principal investigator mails patient with Letter 2 to ask him/her if they would like to attend an 8-week smoking cessation clinic and asks if they would be willing to have a test for genetic susceptibility to development of lung cancer and encloses SAE for reply.

Mailing 3. The principal investigator mails Group B subjects and Group A test-concordant subjects to confirm dates of the smoking cessation sessions and full patient information leaflet and consent form enclosed. The information sheet will be slightly different for group A and B. Non-test concordant subjects within group A will be invited to attend the practice nurse for smoking cessation.

3/Inclusion and exclusion criteria
----------------------------------

i\. **Inclusion criteria:** Aged 20-70 years, smoking more than 10 cigarettes daily.

ii\. **Exclusion criteria:** Aged under 20 years or over 70 years, smoking less than 10 cigarettes daily, history of major depression and other psychiatric conditions, dementias and serious or terminal illness (cancers etc.). Patients on warfarin would be excluded due to interactions between warfarin and varenicline as varenicline will be used as the modern treatment of choice for smoking cessation. Patients who smoke less than 10 cigarettes/day and patients who did not wish to have a genetic test or do not wish to take part in a research study will be referred to the practice nurse for smoking cessation.

4/Smoking cessation clinics
---------------------------

For group A subjects, only subjects who have expressed an interest in having a genetic test and gene-based estimation of susceptibility to lung cancer in mailing 2 will be invited to participate (see referral for decliners above). For group B subjects, all subjects willing to participate are invited to do so. Uptake into smoking cessation programme (i.e. proportion of invitees who accept invitation and attend clinic of those mailed invitation) will be recorded. All subjects who attend the first session of the research clinic will be asked by the principal investigator, JN, to sign a consent form and will be invited to raise any concerns about the protocol (as explained in the full information sheet). The consent form will then be countersigned by JN.

Group A clinics and Group B clinics will be held on different weekdays at the same health centre premises.

Test Subjects who attend Clinic A will be offered a fact sheet on the health risks of smoking (including lung cancer) and the option of the gene-based test for calculation of lung cancer susceptibility whilst subjects who attend Clinic B will be given the same fact sheet on the health risks of smoking (including lung cancer) but without any reference to the gene-based test. The principal investigator will be responsible for handing out the fact sheets and administering the gene-based test in Clinic A and for handing out and explaining the fact sheet in Clinic B.

NHS Surrey's Smoking Cessation Practitioners will lead in-house smoking cessation clinics A and B using the NHS smoking cessation guidelines \[[@B22]\] under the supervision of the principal investigator at the medical centre. There will be:

•Introductory session which includes a new near patient test for salivary cotinine (nicotine metabolite) -- trade name SmokeScreen \[[@B23]\].

•At session 2, patients will be given advice on therapies for smoking cessation. We expect that most patients will opt for a course of varenicline and they will be advised to contact their GP for a prescription.

•This is followed by seven more weekly sessions and a follow-up session at six months (Figure [4](#F4){ref-type="fig"}). Uptake and adherence to smoking cessation will be monitored by weekly carbon monoxide exhalation measurements (breath test). The principal investigator will be involved in clinic A administering the gene-based test and determining if subjects have COPD from practice records and history in session 1. Participants who are heavy smokers, have a smokers cough and use a salbutamol inhaler can be judged to have COPD even if this is not entered in their GP records (all Group A & B subjects will have spirometry at their 6-month follow-up). Subsequently the principal investigator will report back to clinic A patients with estimated lung cancer risks (session 3). To ensure balance in the control clinic the principal investigator will also attend Clinic B sessions 2 and 3 (see Figure [5](#F5){ref-type="fig"} flow charts).

•At the eight week clinic and the 6-month follow-up clinic smoking cessation status and carbon monoxide breath test score will be recorded and a feedback questionnaire used to assess efficacy of various components will be administered.

Mailing 4. Telephone calls followed by letters to patients with invitation to 6-month follow-up session with NHS Smoking Cessation Practitioners and the principal investigator when cessation rate will be assessed and verified by repeating the carbon monoxide breath and salivary cotinine tests.

-- for further details see Figure [5](#F5){ref-type="fig"}: flow charts

![Timeline of project.](1471-2466-14-77-4){#F4}

![**Flow chart for the duration of the trial. a**. Flow chart of project from start to week 12. **b**. Flow chart of project to week 36.](1471-2466-14-77-5){#F5}

We anticipate good attendance at the eight week free smoking cessation clinic, as would be expected if it were a regular NHS smoking cessation clinic but the attendance at the 6-month follow-up clinic may be more challenging. We consider this attendance essential and as attendance will take up an evening of their time, study participants should be paid for their travel expenses (£20) and will receive up to three reminders. Group B subjects attending at the 6-month follow up who have been unable to quit will be offered the gene-based test at this stage.

Technique for taking the respiragene test
-----------------------------------------

The test requires a Buccal swab and the subjects should not eat or drink within 15 minutes prior to supplying a sample (if has eaten or taken a drink within 15 minutes then rinse mouth with tap water). The nurse taking the sample should wear latex or plastic gloves and take care to avoid contact with the buccal swab collection tip to avoid DNA (deoxyribonucleic acid) contamination. Then:

1\. Open buccal swab package at the handle end and carefully remove the swab.

2\. Holding handle end of swab stick, scrape the collection tip firmly against the inside of the cheek 5-6 times (about 10 seconds), being careful not to press the plunger that ejects the tip.

3\. After taking the sample, eject the swab tip into a labelled 2 ml microcentrifuge tube by firmly pressing the plunger at the end of the handle.

4\. Complete and affix the sample tube label onto the microtube. The sample label requires the anonymised trial code for the subject.

Storage of the respiragene test
-------------------------------

After sample collection, tips can be kept at room temperature if they are posted immediately. If storage is necessary, freeze the tubes containing the tips at -20°C.

Packaging instructions for return of samples to Lab21 Ltd
---------------------------------------------------------

1\. Place absorbent material around the tube and then place tube in the plastic bag provided with the kit. Seal the plastic back as per the instructions on the bag

2\. Place the plastic bag containing the sample tube into the shipping box.

3\. Seal the box with the security seal supplied.

4\. Using the Freepost service provided, send the samples to: Lab 21, 184 Cambridge Science Park, Cambridge CB4 0GA.

Patients will be asked to sign a disclaimer form that explains clearly that this test can only give an estimation of cancer risk and is a test that is still under development (one copy of form for investigators and one for patient).

Interpretation of result of respiragene test
--------------------------------------------

Lung cancer susceptibility is calculated using the Respiragene test Auckland formula \[[@B7]\]:

Lung cancer score = (number of susceptible genotypes) - (number of protective genotypes) + 3 (for positive family history) + 4 (for past history of COPD) + 4 (for age \> 60 years old).

The laboratory reports include the scores with an explanation of how the scores relate to a risk category (see Table [1](#T1){ref-type="table"}). When the subject is aged \<60 years, the report will also include the score and risk category that would apply if the subject is still a smoker at age 60 years or over.

Follow-up questionnaires
------------------------

The questionnaires will be slightly different for groups A (questionnaire 2a) and B (questionnaire 2b) as only 2a will contain a direct reference to the gene-based test. Patients who fail to attend at eight weeks and six months will be contacted by telephone to remind them to complete their questionnaires and hand them in to the practice manager. They are designed to determine which subjects have quit smoking or cut down and which subjects who have failed to quit still plan to do so. There is a section that asks about general motivators and components of the smoking cessation programme. The subjects will be asked to score these motivators and smoking cessation aids for their efficacy in helping them to quit. The questions in this section are almost identical to a validated questionnaire \[[@B24]\]. There are also further questions on whether the subject would recommend the *Respiragene* test to a relative or friend and an open ended question for subjects to add their own comments about the concept of a test that predicts susceptibility to lung cancer in a smoker.

Data quality assurance
----------------------

The study has been designed and will be reported in accordance with CONSORT (Consolidated Statement of Reporting Trials) \[[@B25]\]. Data will be controlled in accordance with data protection legislation, institutional protocols of Sussex NHS Research Consortium, and NHS policies for research and information governance for ensuring patient confidentiality \[[@B26]\]. Data will be analysed in SPSS (Statistical Package for Social Sciences) version 15 using an intention to treat approach.

Outcome measures
----------------

### Primary endpoint

Comparison of smoking cessation rates (7 day point abstinence and continuous abstinence) in Clinic A and Clinic B at 8 weeks and six months.

### Secondary endpoints

A. Personal data:

1\. Number of smokers still smoking who state that they still plan to stop.

2\. Daily cigarette consumption of those still smoking.

3\. Mean scores for ranking of smoking cessation aids (gene-based test - Clinic A only, salivary cotinine, lung cancer facts - controls in Clinic B only and general counselling from NHS smoking counsellors).

B. Analyse questions about whether subjects would recommend the test to a member of family or a friend.

C. Analyse last (open ended) question using qualitative research methodology.

Statistics
----------

### Primary end point

The difference between smoking cessation between Clinic A and Clinic B will be estimated from the four week and six month follow up for the primary endpoint (smoking status confirmed by carbon monoxide breathalyser and salivary cotinine tests). If there is the expected higher rate of smoking cessation for Clinic A compared with Clinic B, statistical significance will be demonstrated by the χ^2^ test.

Since there are, as yet, no case-control studies that compare quit rate following the gene-based test versus quit rate without the test, the expected difference in quit rate between Clinic A and Clinic B is difficult to estimate. Two case-control studies showing only a 5-10% increase in smoking cessation involved just a single gene of small effect \[[@B11],[@B12]\]. In a randomised control trial patients were given either a full explanation of the results of spirometry testing, including an estimation of lung age or just the FEV1, without explanation (control group). The group of patients who were given the full explanation had a 7.2% higher quit rate than the control group. However, data from Auckland suggest a larger uplift of quit rate with *Respiragene.* This can be explained by the superior predictive power of a 20-gene test combined with clinical history (personal history of COPD and family history of lung cancer) to give a rather more impressive estimate of cancer risk than anything previously available.

The adequacy of sample size was tested using data from smoking cessation trials that showed:

•30-40% smoking cessation at 6-months with similar protocols \[[@B27],[@B28]\].

•A 48% quit rate at 2-4 weeks in subjects with high and very high lung cancer risk scores but this difference shrinks to 27% at 6 months.

•Data from Young et al \[[@B15],[@B18]\] (independently verified by McBride et al \[[@B11]\]) that even being given an average score for lung cancer susceptibility increases smoking cessation by approximately 10%.

Therefore, with a minimum sample sizes of 30 per group the following calculations based on these estimated quit rates apply (Table [2](#T2){ref-type="table"}). Statistical power of 87.1% is generally acceptable for publication (for alpha error of 5% - i.e. 5% probability of incorrectly rejecting the null hypothesis that there is no difference in the percentage values). For further detailed statistical analysis, refer to Additional file [1](#S1){ref-type="supplementary-material"}.

###### 

Summary of values from which the power of the study are estimated

                          **Control group expected quit rate as %ge**    ***Respiragene*group expected quit rate as %ge**   **χ**^**2**^**calculated from four-some table**  **P value based on χ**^**2**^   **Power calculations\***   
  ----------------------- --------------------------------------------- -------------------------------------------------- ------------------------------------------------- ------------------------------- -------------------------- -------
          8 weeks         Sample size 30/30\*                                                  70%                                                94%                        5.9                             \<0.05                     79.3%
    Sample size 60/60\*   11.7                                                                \<0.01                                             96.9%                                                                                  
         6 months         Sample size 30/30\*\*                                                35%                                                52%                        1.7                             NS                         36.5%
   Sample size 60/60\*\*  6.2                                                                 \<0.05                                             87.1%                                                                                  

\*Telephone (alone) quit rate (see Table [1](#T1){ref-type="table"}) assumed to be 20%.

\*\*Telephone (alone) quit rate (see Table [1](#T1){ref-type="table"}) assumed to be 10-15%.

### Secondary outcome measures

Similarly, the significance of secondary endpoints on intention to stop smoking, cigarette consumption, uptake of invitation to cessation, adherence to cessation course and self-reported smoking cessation will be calculated by the χ^2^ test but the p value for the ranking scores for information on lung cancer risk and other smoking cessation aids and motivators will be estimated from the unpaired student t-test.

The open ended question: "How do you feel now about having had a genetic test that estimates the probability that you will develop lung cancer at some future date?" will have to be analysed by qualitative analysis to determine the main recurrent themes in responses.

Discussion
==========

Overview
--------

Smoking cessation is one of the most cost effective interventions that can be achieved in primary care \[[@B29]\]. However many smokers are very reluctant to commit to a smoking cessation programme (precontemplative and contemplative) and about half of those that attend for smoking cessation intervention (action stage of change) are likely to drop out or give up trying. Therefore, any methodology that increases motivation in both unmotivated and motivated smokers could be very valuable. The gene-based test we are offering has shown promise as a smoking cessation motivator in precontemplative-contemplative smokers in a hospital outpatient setting \[[@B15],[@B18]\] and now needs to be tested out as a motivator for improving adherence in a primary care smoking cessation clinic using a randomised controlled study.

Strengths
---------

The main strengths of this study are that it is being carried out on subjects from a large primary care population and should therefore be more representative of the general population than previous studies recruited from hospital patients and other special groups. We also have the advantage of being able to carry out this research within the established framework of the local stop smoking service.

Limitations and assumptions
---------------------------

Although we have estimated, based on previous smoking cessation work using this gene-based test, that the primary endpoint will show that having the test improves quit rate by 20-25%, this was based on a cohort of hospital outpatients in Auckland, New Zealand and subjects recruited from primary care may respond differently. Although we plan to recruit a minimum of 60 subjects, this may not be enough to balance unexpected and unknown confounding factors.

What we might find
------------------

We aim to recruit a minimum of 60 subjects to randomise 30 into group A (test group) and 30 into Group B (control group). The normal experience in NHS smoking cessation clinics is a drop-out rate of 40-50% \[[@B30]-[@B32]\]. We need, therefore, to attempt to recruit about 120 subjects in order to get a statistically significant result, based on the assumptions in our power calculations. We may, however, have underestimated the 6-month quit rate using the NHS local stop smoking guidelines \[[@B22]\] which typically involves a multi-interventional programme which includes combinations of varenicline prescriptions, breath carbon monoxide monitoring and intensive counselling giving a quit rate of 70-80% at 6-weeks.There are however no Surrey data for 6-month quit rate which we assume, on the basis of similar smoking cessation data to be about half the 6-week figure \[[@B33]\] ≅ 35%.

An unknown and unpredictable factor, that could skew results significantly, is the possibility that our multi-interventional approach could help to reinforce the health risk message equally for subjects in both groups. Also, the Auckland study design involved recruitment of precontemplative-contemplative smokers from a hospital outpatient setting, compared to this study that will involve primary care subjects who have volunteered to participate in a smoking cessation programme (ie smokers in the action stage of quitting). This population, therefore, could be sufficiently different to give unexpected results. However, the results of this trial will inform as to the acceptability of this approach as well as its effectiveness.
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